"Cell Therapeutics cancer drug development and research people & facilities"

<head> <title>Cell Therapeutics cancer drug development and research people & facilities</title> <meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1"> <link rel='stylesheet' href='css/about.css' type='text/css'> <script language="JavaScript">  </script> </head> <body leftmargin="0" topmargin="0" marginwidth="0" marginheight="0" onload="MM_preloadImages('images/abou_sidenav-fhist-on.gif','images/abou_sidenav-bstra-on.gif','images/abou_sidenav-coll-on.gif','images/abou_sidenav-tech-on.gif','images/abou_sidenav-comm-on.gif')" bgcolor="#FFFFFF" background="images/bg_abou.gif"> <table width="100%" border="0" cellspacing="0" cellpadding="0"> <tr> <td valign="bottom"><a href="default.htm" target="_parent" name="top"><img src="images/cti_logo-a.gif" width="65" height="80" alt="Cell Therapeutics making cancer more treatable" border="0"></a></td> <td valign="bottom"><img src="images/0.gif" width="1" height="1" alt="" border="0"></td> <td valign="bottom" bgcolor="#6FA090"><img src="images/cti_logo-title-a.gif" width="172" height="19" alt="Making Cancer More Treatable"></td> <td><img src="images/0.gif" width="1" height="1" alt="" border="0"></td> <td bgcolor="#6FA090"><img src="images/0.gif" width="1" height="1" alt="" border="0"></td> <td valign="bottom" bgcolor="#6FA090"> <table border="0" cellspacing="0" cellpadding="0"> <tr> <td><a href="about.htm" target="_parent"><img src="images/abou_title-sm.gif" width="46" height="22" alt="About cti" border="0"></a></td> <td><img src="images/abou_title-div.gif" width="10" height="22" alt="/"></td> <td><img src="images/abou_title-pfaci.gif" width="127" height="22" alt="Cell Therapeutics management and cancer drug research & development facilities" border="0"></td> </tr> </table> </td> <td bgcolor="#6FA090"><img src="images/0.gif" width="1" height="1" alt="" border="0"></td> </tr> <tr> <td width="65" bgcolor="#FFFFFF"><img src="images/0.gif" width="65" height="1" alt="" border="0"></td> <td width="1" bgcolor="#FFFFFF"><img src="images/0.gif" width="1" height="1" alt="" border="0"></td> <td width="202" bgcolor="#FFFFFF"><img src="images/0.gif" width="202" height="1" alt="" border="0"></td> <td width="1" bgcolor="#FFFFFF"><img src="images/0.gif" width="1" height="1" alt="" border="0"></td> <td width="50" bgcolor="#FFFFFF"><img src="images/0.gif" width="50" height="1" alt="" border="0"></td> <td width="100%" bgcolor="#FFFFFF"><img src="images/0.gif" width="400" height="1" alt="" border="0"></td> <td width="50" bgcolor="#FFFFFF"><img src="images/0.gif" width="50" height="1" alt="" border="0"></td> </tr> </table> <table width="770" border="0" cellspacing="0" cellpadding="0"> <tr> <td valign="top"> <table width="270" border="0" cellspacing="0" cellpadding="0"> <tr> <td height="128"><img src="images/0.gif" width="5" height="128" alt="" border="0"></td> <td><img src="images/0.gif" width="1" height="1" alt="" border="0"></td> <td><img src="images/abou_photo-2.jpg" width="202" height="128" alt="About CTI Cancer Research, Cancer Therapies, and Cancer Drug Development"></td> <td><img src="images/0.gif" width="1" height="1" alt="" border="0"></td> </tr> <tr> <td bgcolor="#FFFFFF"><img src="images/0.gif" width="1" height="1" alt="" border="0"></td> <td bgcolor="#FFFFFF"><img src="images/0.gif" width="1" height="1" alt="" border="0"></td> <td bgcolor="#FFFFFF"><img src="images/0.gif" width="1" height="1" alt="" border="0"></td> <td bgcolor="#FFFFFF"><img src="images/0.gif" width="1" height="1" alt="" border="0"></td> </tr> <tr> <td valign="TOP"> <table width="65" border="0" cellspacing="0" cellpadding="0"> <tr> <td><img src="images/0.gif" width="5" height="20" alt="" border="0"></td> </tr> <tr align="right"> <td><img src="images/0.gif" width="15" height="20" alt="" border="0"></td> </tr> <tr align="right"> <td><img src="images/abou_sidenav-arrow.gif" width="15" height="20" alt="" border="0"></td> </tr> <tr align="right"> <td><img src="images/0.gif" width="15" height="20" alt="" border="0"></td> </tr> <tr align="right"> <td><img src="images/0.gif" width="15" height="20" alt="" border="0"></td> </tr> <tr align="right"> <td><img src="images/0.gif" width="15" height="20" alt="" border="0"></td> </tr> <tr align="right"> <td><img src="images/0.gif" width="15" height="20" alt="" border="0"></td> </tr> <tr align="right"> <td><img src="images/0.gif" width="15" height="20" alt="" border="0"></td> </tr> <tr align="right"> <td><img src="images/0.gif" width="65" height="1" alt="" border="0"></td> </tr> </table> </td> <td><img src="images/0.gif" width="1" height="1" alt="" border="0"></td> <td valign="TOP"> <table width="202" border="0" cellspacing="0" cellpadding="0"> <tr> <td><img src="images/0.gif" width="5" height="20" alt="" border="0"></td> </tr> <tr> <td><a href="abou_frame-bstra.htm" onmouseout="MM_swapImgRestore()" onmouseover="MM_swapImage('bstra','','images/abou_sidenav-bstra-on.gif',1)"><img src="images/abou_sidenav-bstra.gif" width="134" height="20" border="0" name="bstra" alt="Cell Therapeutics Business Strategy"></a></td> </tr> <tr> <td><a href="abou_frame-pfaci.htm"><img src="images/abou_sidenav-pfaci-on.gif" width="134" height="20" border="0" name="pfaci" alt="Cell Therapeutics management and cancer drug research & development facilities"></a></td> </tr> <tr> <td><a href="abou_frame-coll.htm" onmouseout="MM_swapImgRestore()" onmouseover="MM_swapImage('coll','','images/abou_sidenav-coll-on.gif',1)"><img src="images/abou_sidenav-coll.gif" width="134" height="20" border="0" name="coll" alt="Cell Therapeutics Collaborations"></a></td> </tr> <tr> <td><a href="abou_frame-tech.htm" onmouseout="MM_swapImgRestore()" onmouseover="MM_swapImage('tech','','images/abou_sidenav-tech-on.gif',1)"><img src="images/abou_sidenav-tech.gif" width="134" height="20" border="0" name="tech" alt="Technologies for Cancer Research, Treatment, and Cancer Drug Development"></a></td> </tr> <tr> <td><a href="abou_frame-fhist.htm" onmouseout="MM_swapImgRestore()" onmouseover="MM_swapImage('fhist','','images/abou_sidenav-fhist-on.gif',1)"><img src="images/abou_sidenav-fhist.gif" width="134" height="20" border="0" name="fhist" alt="Cell Therapeutics Financial History"></a></td> </tr> <tr> <td><a href="abou_frame-mvalu.htm" onmouseout="MM_swapImgRestore()" onmouseover="MM_swapImage('mvalu','','images/abou_sidenav-mvalu-on.gif',1)"><img src="images/abou_sidenav-mvalu.gif" width="147" height="20" border="0" name="mvalu" alt="Cell Therapeutics Mission & Values"></a></td> </tr> <tr> <td><a href="abou_frame-comm.htm" onmouseout="MM_swapImgRestore()" onmouseover="MM_swapImage('Image52','','images/abou_sidenav-comm-on.gif',1)"><img name="Image52" border="0" src="images/abou_sidenav-comm.gif" width="147" height="20" alt="Cell Therapeutics Community Involvement - Helping community organizations that assist people dealing with cancer"></a></td> </tr> </table> </td> <td><img src="images/0.gif" width="1" height="1" alt="" border="0"></td> </tr> <tr> <td width="65"><img src="images/0.gif" width="65" height="1" alt="" border="0"></td> <td width="1"><img src="images/0.gif" width="1" height="1" alt="" border="0"></td> <td width="202"><img src="images/0.gif" width="202" height="1" alt="" border="0"></td> <td width="1"><img src="images/0.gif" width="1" height="1" alt="" border="0"></td> </tr> </table> </td> <td> </td> <td valign="TOP" class="a"> <br> <br> <table width="100%" border="0" cellspacing="0" cellpadding="0"> <tr> <td class="a" valign="top"> <p> Established in September 1991, we currently have facilities and staff in the U.S. and Europe. Our corporate headquarters are in Seattle, Washington with research and development facilities in Seattle and Bresso (Milan), Italy, and offices in London.<br> <br> We support our committed professionals with state-of-the-art facilities and laboratories. We recognize the value of each of our employees and take pride in creating a positive work environment. Our strength lies in the individuals who work to accomplish our collective goals. </p> <table width="100%" border="0" cellspacing="0" cellpadding="0"> <tr> <td> <h1><a name="doffi"></a><b>Board of Directors</b></h1> </td> </tr> <tr> <td class="a"><a href="#mlink">Max Link, Ph.D.</a> <font size="1">Chairman of the Board of Directors</font></td> </tr> <tr> <td class="a"><a href="#jbian">James A. Bianco, M.D.</a> <font size="1">CTI principal founder, President and CEO</font></td> </tr> <tr> <td class="a"><a href="#fluke">John M. Fluke, Jr.</a> <font size="1">Director</font></td> </tr> <tr> <td class="a"><a href="#vgreg">Vartan Gregorian, Ph.D.</a> <font size="1">Director</font></td> </tr> <tr> <td class="a"><a href="#mmund">Mary O'Neil Mundinger, D.P.H.</a> <font size="1">Director</font></td> </tr> <tr> <td class="a"><a href="#pnude">Phillip M. Nudelman, Ph.D.</a> <font size="1">Director</font></td> </tr> <tr> <td class="a"><a href="#eplatz">Erich Platzer, M.D.</a> <font size="1">Director</font></td> </tr> <tr> <td class="a"><a href="#jsing">Jack W. Singer, M.D.</a> <font size="1">CTI founder and Director, Chief Medical Officer</font></td> </tr> <tr> <td class="a"><a href="#sspin">Silvano Spinelli</a> <font size="1">Director, CTI EVP Development</font></td> </tr> <tr> <td>  </td> </tr> <tr> <td> <h1><b>Executive Management</b></h1> </td> </tr> <tr> <td class="a"><a href="#jbian">James A. Bianco, M.D.</a> <font size="1">President and Chief Executive Officer</font></td> </tr> <tr> <td class="a"><a href="#lbianc">Louis A. Bianco</a> <font size="1">EVP Finance & Administration</font></td> </tr> <tr> <td class="a"><a href="#brown">Jade Brown</a> <font size="1">VP Business Development</font></td> </tr> <tr> <td class="a"><a href="#leigh">Richard E. Leigh, Jr.</a> <font size="1">EVP and General Counsel</font></td> </tr> <tr> <td class="a"><a href="#levonyak">Mark Levonyak</a> <font size="1">VP Marketing</font></td> </tr> <tr> <td class="a"><a href="#jsing">Jack W. Singer, M.D.</a> <font size="1">EVP, Chief Medical Officer</font></td> </tr> <tr> <td class="a"><a href="#sspin">Silvano Spinelli</a> <font size="1">Director, CTI EVP Development</font></td> </tr> <tr> <td class="a"><a href="#stromatt">Scott C. Stromatt, M.D.</a> <font size="1">Sr. VP, Clinical Development & Regulatory Affairs</font></td> </tr> </table> <h1><b><br> Management Biographies</b></h1> </td> </tr> </table> <br> <table width="100%" border="0" cellspacing="0" cellpadding="0"> <tr valign="TOP"> <td class="a"> <p> <b>James A. Bianco, M.D.</b>, is the principal founder of Cell Therapeutics, Inc. and has been the Company's President and Chief Executive Officer and Director since February 1992. Dr. Bianco has been responsible for securing nearly $1 billion in operating capital. He introduced the model of vertical integration as a cornerstone in the Company's business strategy, providing a platform for developing commercially successful solutions for the management of cancer and side effects of cancer therapy. He was also the chief architect of the company's portfolio strategy leading to the acquisition of its PG drug delivery technology (XYOTAX) in 1998, TRISENOX<font size="1">®</font> in 2000, and Novuspharma's Pixantrone in 2003. <br> <br> Prior to joining CTI, Dr. Bianco was an Assistant Member in the clinical research division of the Fred Hutchinson Cancer Research Center (FHCRC) and an Assistant Professor of Medicine at the University of Washington. From 1990 to 1992, Dr. Bianco was the director of the Bone Marrow Transplant Program at the Veterans Administration Medical Center in Seattle. He received his B.S. in Biology and Physics from New York University and his M.D. from Mount Sinai School of Medicine in New York. </p> <p>Dr. Bianco received the 2005 Corporate Visionary Award from Gilda’s Club Seattle, an organization where people with cancer and their families can receive emotional and social support. “Dr. Bianco has made it his life’s mission to make cancer more treatable by pursuing less toxic and more effective chemotherapy drugs,” said Anna Gottlieb, founder and executive director of Gilda’s Club Seattle. “He also understands that people living with cancer need more than medicine. His support of Gilda’s Club Seattle is actually helping to make cancer more livable.”<br> <br> <img src="images/bianco_mag.jpg" width="100" height="131" alt="" border="1" align="left" hspace="5">And, in a region that boasts some of this nation's leading companies, James Bianco was named CEO of the Year for 2000 by Washington CEO magazine. </p></td> </tr> </table> <br> <table border="0" cellspacing="0" cellpadding="0"> <tr> <td width="14"><a href="#top"><img src="images/abou_backtotop-arrow.gif" width="14" height="10" alt="back to top" border="0"></a></td> <td class="a"><a href="#top">back to top</a></td> </tr> </table> <br> <a name="lbianc"></a> <br> <table width="100%" border="0" cellspacing="0" cellpadding="0"> <tr valign="TOP"> <td class="a"> <p> <b>Louis A. Bianco</b> is a founder of CTI and has been CTI's Executive Vice President, Finance and Administration since February 1, 1992, and a Director of CTI from the Company's inception in September 1991 to April 1992, and from April 1993 to April 1995. From January 1989 through January 1992, Mr. Bianco was a Vice President at Deutsche Bank Capital Corporation in charge of risk management. Mr. Bianco is a Certified Public Accountant and received his M.B.A. from New York University. </p></td> </tr> </table> <br> <table border="0" cellspacing="0" cellpadding="0"> <tr> <td width="14"><a href="#top"><img src="images/abou_backtotop-arrow.gif" width="14" height="10" alt="back to top" border="0"></a></td> <td class="a"><a href="#top">back to top</a></td> </tr> </table> <br> <br> <p><a name="brown"></a></p> <p><strong>Jade Brown</strong> As Vice President of Business Development at CTI Mr. Brown drives the partnering strategy for the Company, overseeing the analysis and selection of collaborators to meet CTI’s business objectives. Prior to joining CTI, Mr. Brown was Vice President of Business Development & Marketing at Nastech Pharmaceuticals where he was responsible for all business development and marketing activities including, licensing, divestures, product assessments, marketing plans and portfolio planning. For 12 years, he was employed by Eli Lilly and Company where he held a number of leadership positions in business development and commercialization, ultimately serving as the Brand Director in the Women’s Health Division. Mr. Brown has undertaken multiple high profile collaborations with a variety of pharmaceutical and biotechnology companies. Mr. Brown received his M.B.A. from Harvard University Graduate School of Business and his B.S. from Indiana University. </p> <table border="0" cellspacing="0" cellpadding="0"> <tr> <td width="14"><a href="#top"><img src="images/abou_backtotop-arrow.gif" width="14" height="10" alt="back to top" border="0"></a></td> <td class="a"><a href="#top">back to top</a></td> </tr> </table> <p><br> <a name="fluke"></a> </p> <table width="100%" border="0" cellspacing="0" cellpadding="0"> <tr> <td class="a" valign="top"> <p> <b>John M. Fluke, Jr.</b> joined the Board of Directors in November 2002. Mr. Fluke is the Chairman of Fluke Capital Management, LP, a venture capital company headquartered in the Greater Seattle area. He earned two degrees in electrical engineering: a BSEE from the University of Washington in 1964 and a MSEE from Stanford University in 1966. He joined his father's firm, Fluke Corporation in 1966 as a practicing engineer. He held various engineering and management posts in that company, ultimately being appointed its Chairman and Chief Executive in 1983. In 1990 he turned over day-to-day management of Fluke Corporation to devote his full attention to Fluke Capital. </p> <p> From 1984, Mr. Fluke has been a director of PACCAR Inc. He also served on the board of Peoples Bank from 1984 to 1987, and joined US Bank of Washington's board following acquisition of Peoples by US Bank. In addition to his leadership role with his venture capital firm, Mr. Fluke currently serves as an advisor to the CEO for selected early-stage companies. </p> <p> Mr. Fluke has held leadership positions in many community, business, arts, and education organizations. Today he continues as a member of the University of Washington's Business School Advisory Board, The College of Engineering and the Applied Physics Laboratory. He continues his community services as a trustee of the Museum of Flight, Junior Achievement of Puget Sound, The Nature Conservancy, and the Swedish Hospital Foundation. </p></td> </tr> </table> <br> <table border="0" cellspacing="0" cellpadding="0"> <tr> <td width="14"><a href="#top"><img src="images/abou_backtotop-arrow.gif" width="14" height="10" alt="back to top" border="0"></a></td> <td class="a"><a href="#top">back to top</a></td> </tr> </table> <br> <a name="vgreg"></a> <br> <table width="100%" border="0" cellspacing="0" cellpadding="0"> <tr> <td class="a"> <p> <b>Vartan Gregorian, Ph.D.</b> is the twelfth president of Carnegie Corporation of New York, a grant-making institution founded by Andrew Carnegie in 1911. Prior to his current position, which he assumed in June 1997, Gregorian served for nine years as Brown University's sixteenth president. </p> <p> He was awarded a Ph.D. in history and humanities from Stanford in 1964. He was founding dean of the Faculty of Arts and Sciences at the University of Pennsylvania in 1974 and four years later became its twenty-third provost. He served as president of the New York Public Library from 1981 to 1989, when he left to become president of Brown. </p> <p> A Phi Beta Kappa and a Ford Foundation Foreign Area Training Fellow, he is a recipient of numerous fellowships, including those from the John Simon Guggenheim Foundation, the American Council of Learned Societies, the Social Science Research Council and the American Philosophical Society. He is also a fellow of the American Academy of Arts and Sciences. He serves on the boards of the Institute for Advanced Study at Princeton, Human Rights Watch, McGraw Hill Inc., and the Museum of Modern Art, among others. He has been decorated by the French, Italian, Austrian, and Portuguese governments. </p> <p> His numerous civic and academic honors include some fifty honorary degrees, including those from Brown, Dartmouth, Drew, Johns Hopkins, University of Pennsylvania, the Jewish Theological Seminary, the City University of New York, Rutgers, Tufts, New York University, University of Aberdeen, and, most recently, The Juilliard School, and the University of Illinois at Urbana-Champaign. In 1986 Gregorian was awarded the Ellis Island Medal of Honor and in 1989 the American Academy and the Institute of Arts and Letters' Gold Medal for Service to the Arts. In 1998 President Clinton awarded him the National Humanities Medal, and in 2004 President Bush presented him with the Presidential Medal of Freedom.</p></td> </tr> </table> <br> <table border="0" cellspacing="0" cellpadding="0"> <tr> <td width="14"><a href="#top"><img src="images/abou_backtotop-arrow.gif" width="14" height="10" alt="back to top" border="0"></a></td> <td class="a"><a href="#top">back to top</a></td> </tr> </table> <br> <br> <a name="leigh"></a> <table width="100%" border="0" cellspacing="0" cellpadding="0"> <tr> <td class="a" valign="top"><p><b>Richard E. Leigh, Jr.</b> joined CTI as Executive Vice President and General Counsel in August 2004. Leigh will serve as a member of the CTI's senior management team overseeing all legal matters related to the organization including intellectual property and corporate contracts as well as the coordination of any legal matters handled by outside counsel.</p> <p>Leigh comes to CTI from Vulcan Inc., a Paul G. Allen management and development company where he served as Vice President and General Counsel. Vulcan Inc. manages investments in private and publicly held organizations spanning life science companies to multimedia and entertainment-related businesses. Prior to Vulcan, Leigh was Vice President and General Counsel for the NFL’s Seattle Seahawks where he worked on the Stadium Project, now known as Qwest Field. In addition, he spent eight years as a corporate attorney with the Seattle law firm of Foster Pepper & Shefelman, PLLC, where he was a partner focused on mergers and acquisitions and finance. Leigh earned his B.A. at Brown University in Providence, Rhode Island, his M.A. in International Politics from The Johns Hopkins University School of Advanced International Studies in Washington, D.C., and a J.D. from Columbia University School of Law in New York.<br> </p></td> </tr> </table> <br> <table border="0" cellspacing="0" cellpadding="0"> <tr> <td width="14"><a href="#top"><img src="images/abou_backtotop-arrow.gif" width="14" height="10" alt="back to top" border="0"></a></td> <td class="a"><a href="#top">back to top</a></td> </tr> </table> <br> <br> <p><strong><a name="levonyak"></a></strong></p> <p><strong>Mark Levonyak</strong> joined CTI in 2000 as the Western Sales Director responsible for developing and leading the National Sales Force and Medical Affairs teams to promote and educate oncologists and hematologists on the benefits of TRISENOX, CTI’s first commercial product designed for the treatment of acute promyelocytic leukemia.</p> <p>In 2001 Mr. Levonyak was promoted to Director, Oncology & Hematology Marketing and was instrumental in guiding the expansion of the CTI Marketing department as it relates to product management, new product planning, market development, and market analytics. He transformed brand strategies into tactical programs to ensure optimal positioning and awareness of the CTI product portfolio.</p> <p>In early 2004 Mark was promoted to Vice President, Oncology & Hematology Marketing and was given the added responsibility to lead the XYOTAX Global Core team. He is responsible for the development and integration of business and strategic plans for the CTI product portfolio with a emphasis on pre-launch activities for XYOTAX in the treatment of NSCLC.</p> <p>The 15 years prior to joining CTI, Mr. Levonyak worked in numerous commercial roles at SmithKline Beecham Pharmaceuticals. From 1995 to 2000 he worked as the Oncology Commercial Director, where he developed and led the sales, medical affairs, and medical education teams in the Western Area. Mr. Levonyak played a critical role in the creation of the oncology business unit at SKB.</p> <p>From 1985 to 1995 Mr. Levonyak was promoted into many different commercial roles ranging from District Sales Manager, National Accounts Manager, Sales Trainer, Recruiter, and Sales Representative. He consistently received leadership and performance awards for his accomplishments. Mr. Levonyak’s received his BA in Biological Sciences and Chemistry from California State University system.</p> <table border="0" cellspacing="0" cellpadding="0"> <tr> <td width="14"><a href="#top"><img src="images/abou_backtotop-arrow.gif" width="14" height="10" alt="back to top" border="0"></a></td> <td class="a"><a href="#top">back to top</a></td> </tr> </table> <p><br> <b><a name="mlink"></a></b> </p> <table width="100%" border="0" cellspacing="0" cellpadding="0"> <tr> <td class="a"> <p> <b>Max Link, Ph.D</b>., joined the Board of Directors in July 1995 as its Vice-Chairman and has served as Chairman of the Board of Directors since January 1996. In addition, Dr. Link has held a number of executive positions with pharmaceutical and healthcare companies. </p> <p> Most recently, he served as Chief Executive Officer of Corange, Limited, ("Corange") from May 1993 until June 1994. Prior to joining Corange, Dr. Link served in a number of positions within Sandoz Pharma Ltd., including Chief Executive Officer from 1990 until April 1992, and Chairman from April 1992 until May 1993. </p> <p> Dr. Link currently serves on the boards of directors of Alexion Pharmaceuticals, Inc., Human Genome Sciences, Inc., Procept, Inc. and Protein Design Labs, Inc. Dr. Link received his Ph.D. in Economics from the University of St. Gallen. </p></td> </tr> </table> <br> <table border="0" cellspacing="0" cellpadding="0"> <tr> <td width="14"><a href="#top"><img src="images/abou_backtotop-arrow.gif" width="14" height="10" alt="back to top" border="0"></a></td> <td class="a"><a href="#top">back to top</a></td> </tr> </table> <br> <a name="mmund"></a> <br> <table width="100%" border="0" cellspacing="0" cellpadding="0"> <tr> <td class="a"> <p> <b>Mary O'Neil Mundinger, D.P.H.,</b> has been a Director since April 1997. Since 1986, she has been Dean and Professor, School of Nursing and Associate Dean, Faculty of Medicine, Columbia University. </p> <p> Dr. Mundinger is a nationally recognized health policy specialist and was recently named as Columbia's Centennial Professor in Health Policy, the first of its kind at a nursing school. She is a cum laude graduate of the University of Michigan and received her doctorate from Columbia's School of Public Health. </p></td> </tr> </table> <br> <table border="0" cellspacing="0" cellpadding="0"> <tr> <td width="14"><a href="#top"><img src="images/abou_backtotop-arrow.gif" width="14" height="10" alt="back to top" border="0"></a></td> <td class="a"><a href="#top">back to top</a></td> </tr> </table> <br> <a name="pnude"></a> <br> <table width="100%" border="0" cellspacing="0" cellpadding="0"> <tr> <td class="a"> <p> <b>Phillip M. Nudelman, Ph.D.</b>, has been a Director of CTI since March 1994. In April 2000, Dr. Nudelman was named President and Chief Executive of The Hope Heart Institute, Seattle's leading nonprofit cardiovascular research and education center. Nudelman recently retired as President and CEO of Group Health Cooperative and as Chairman and President of Kaiser/Group Health. </p> <p> A leader in improving health care in the country, Nudelman has served on the White House Task Force for Health Care Reform and the President's Advisory Commission on Consumer Protection and Quality in Health Care. He has served on the Pew Health Professions Commission and the AMA Task Force on Ethics, currently surves as Chairman of the American Association of Health Plans. Nudelman also serves on the boards of directors of Cytran Ltd., SpaceLabs Medical Inc., and PersonalPath.com, Inc. </p></td> </tr> </table> <br> <table border="0" cellspacing="0" cellpadding="0"> <tr> <td width="14"><a href="#top"><img src="images/abou_backtotop-arrow.gif" width="14" height="10" alt="back to top" border="0"></a></td> <td class="a"><a href="#top">back to top</a></td> </tr> </table> <br> <a name="eplatz"></a> <br> <table width="100%" border="0" cellspacing="0" cellpadding="0"> <tr> <td class="a" valign="top"> <p> <b>Erich Platzer, M.D.</b>, joined CTI's Board as Director in early 2004 upon the merger of CTI and Novuspharma. He formerly served as chairman of the board at Novuspharma. Prior to this he was head of global oncology marketing for Roche, where he was involved in the launch of rituximab (Mabthera) and trastuzumab (Herceptin). Dr. Platzer holds a degree from the University of Erlangen, Germany, where he later became associate professor of medicine. </p></td> </tr> </table> <br> <table border="0" cellspacing="0" cellpadding="0"> <tr> <td width="14"><a href="#top"><img src="images/abou_backtotop-arrow.gif" width="14" height="10" alt="back to top" border="0"></a></td> <td class="a"><a href="#top">back to top</a></td> </tr> </table> <br> <a name="jsing"></a> <br> <table width="100%" border="0" cellspacing="0" cellpadding="0"> <tr valign="TOP"> <td class="a" height="266"> <p> <b>Jack W. Singer, M.D.</b>, is a founder and Director of CTI and was appointed Chief Medical Officer in January 2004. Dr. Singer was formerly Executive Vice President, Research Program Chair. As Chief Medical Officer, Dr. Singer is the primary thought leader for CTI clinical and medical strategy. He is a noted expert in hematologic cancers, having developed the clonal theory of leukemia. He has authored more than 240 peer-reviewed manuscripts and 13 chapters in textbooks on cell biology and clinical drug development and holds 14 patents. He has been an invited speaker at numerous medical conferences, including, the 6th International Symposium on Polymer Therapeutics, and he is a member of the Society for Clinical Investigation. </p> <p> Prior to joining CTI, Dr. Singer was Professor of Medicine at the University of Washington and full Member of the Fred Hutchinson Cancer Research Center. From 1975 to 1992, he was the Chief of Medical Oncology at the Veterans Administration Medical Center in Seattle. In addition, Singer served as an advisor to the National Cancer Institute and was a consultant to several pharmaceutical companies prior to joining CTI. </p></td> </tr> </table> <br> <table border="0" cellspacing="0" cellpadding="0"> <tr> <td width="14"><a href="#top"><img src="images/abou_backtotop-arrow.gif" width="14" height="10" alt="back to top" border="0"></a></td> <td class="a"><a href="#top">back to top</a></td> </tr> </table> <br> <a name="sspin"></a> <br> <table width="100%" border="0" cellspacing="0" cellpadding="0"> <tr> <td class="a" valign="top"> <p> <b>Silvano Spinelli</b> became part of CTI's Board as a result of the January 2004 merger with Novuspharma. He will serve as Executive Vice President Development for CTI and Managing Director, European Operations. In this role he also assumes leadership of Discovery Research. Mr. Spinelli was a co-founder of Novuspharma, and served as its chief executive from January 1999 through December 2003. </p> <p> Prior to the formation of Novuspharma, Mr. Spinelli was director of R&D at Boehringer Mannheim Italia SpA., where he was responsible for the development and registration of several pharmaceutical products. During this time he was involved in the discovery of products which formed part of Novuspharmas clinical pipeline. Mr. Spinelli holds a degree in organic chemistry from the University of Pisa. </p></td> </tr> </table> <br> <table border="0" cellspacing="0" cellpadding="0"> <tr> <td width="14"><a href="#top"><img src="images/abou_backtotop-arrow.gif" width="14" height="10" alt="back to top" border="0"></a></td> <td class="a"><a href="#top">back to top</a></td> </tr> </table> <br> <br> <p><a name="stromatt" id="stromatt"></a> </p> <table width="100%" border="0" cellspacing="0" cellpadding="0"> <tr> <td class="a" valign="top"> <p> <strong>Scott C. Stromatt, M.D.</strong> is CTI’s Senior Vice President, Clinical Development and Regulatory Affairs and has managed the Company’s global clinical research programs and related functional areas since 2003. His experience includes multiple clinical indications, successful NDAs, and in multiple settings, including biotech, pharmaceutical, and contract research companies.</p> <p>Prior to joining CTI, Dr. Stromatt was Vice President Clinical Research and Chief Medical Officer for Northwest Biotherapeutics, focused on an immunotherapy based oncology product. For three years prior to that, he was an analyst focused on public and private biotechnology, pharmaceutical, and medical device companies.</p> <p>Dr. Stromatt has been in private practice as an internist, and has worked in biomedical research for the last 17 years beginning his career at Searle. He earned his MD from the University of Chicago in 1983, then performed his residency at the University of New Mexico where he became Chief Medical Resident. In 1999, he completed his MBA at the University of Colorado.<br> </p></td> </tr> </table> <br> <table border="0" cellspacing="0" cellpadding="0"> <tr> <td width="14"><a href="#top"><img src="images/abou_backtotop-arrow.gif" width="14" height="10" alt="back to top" border="0"></a></td> <td class="a"><a href="#top">back to top</a></td> </tr> </table> <p><br> <font class="cr">Posted July 18, 2005</font><br> <br> <font class="cr">Copyright © 2004, 2005 Cell Therapeutics, Inc., Seattle, WA, USA. All rights reserved. "Making cancer more treatable" is a registered mark of CTI. </font> <br>  </p></td> <td><img src="images/0.gif" width="5" height="128" alt="" border="0"></td> </tr> <tr> <td width="270"><img src="images/0.gif" width="270" height="1" alt="" border="0"></td> <td width="50"><img src="images/0.gif" width="50" height="1" alt="" border="0"></td> <td width="100%"> </td> <td width="50"><img src="images/0.gif" width="50" height="1" alt="" border="0"></td> </tr> </table> </body>